Abstract

 Gram-positive, nonpathogenic lactic acid bacteria (LAB) are considered to be promising candidates for the development of novel, safe production and delivery systems of heterologous proteins. LABs have diverse beneficial applications for human welfare. LAB plays an important role in the industry for the synthesis of chemicals, pharmaceuticals, or other useful products in food industry. Certain Lactobacilli can induce an increase in the cellular or humoral systemic immune response, it acts as a vehicle to insert gene to produce required protein of interest. Many of the researcher find out the best possible way to utilize the beneficiaries of lactic role to combat recent coronavirus pandemic lactic acid bacteria concerning COVID-19. New recombinant strains and vectors continue to be constructed and described in detail what can lead in the near future to standardization of LAB vectors in vaccine production. The development of new LAB recombinant strains and vectors continue to be constructed and described in detail what can lead in the near future to standardization of LAB vectors in vaccine production for COVID-19.

Keywords: COVID-19; LAB; Probiotic, Vaccine Production

References

1. Lehtinen M., et al. “U.S. Patent Application No. 15/544,989” (2019).
2. Missaoui J., et al. “Fermented Seeds (“Zgougou”) from Aleppo Pine as a Novel Source of Potentially Probiotic Lactic Acid Bacteria”. Microorganisms 12 (2019): 709.
3. Li M., et al. “Characterization of Lactic Acid Bacteria Isolated from the Gastrointestinal Tract of a Wild Boar as Potential Probiotics”. Frontiers in Veterinary Science 7 (2020): 49.
4. Ai J., et al. “The cross-sectional study of hospitalized coronavirus disease 2019 patients in Xiangyang, Hubei province”. Med Rxiv (2020).
5. Cowling BJ and Leung GM. “Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak”. Eurosurveillance6 (2020).
6. Cui J., et al. “Origin and evolution of pathogenic coronaviruses”. Nature Reviews Microbiology3 (2019): 181-192.
7. Lim XF., et al. “Detection and characterization of a novel bat-borne coronavirus in Singapore using multiple molecular approaches”. Journal of General Virology10 (2019): 1363-1374.
8. Bozkurt HS. “Probiotic bacteria against the COVID-19” (2020).
9. Bouladoux N., et al. “Commensal-dendritic-cell interaction specifies a unique protective skin immune signature 520.7545 (2016): 108-104.
10. Remuzzi A and Remuzzi G. “COVID-19 and Italy: what next?” The Lancet (2020).
11. Gao QY., et al. “2019 novel coronavirus infection and gastrointestinal tract”. Journal of Digestive Diseases (2020).
12. Jiang F., et al. “Review of the clinical characteristics of coronavirus disease 2019 (COVID-19)”. Journal of General Internal Medicine (2020): 1-5.
13. Nikhra V. The Trans-Zoonotic Virome Interface: Measures to Balance, Control and Treat Epidemics (2020).
14. Johnson CK., et al. “Spillover and pandemic properties of zoonotic viruses with high host plasticity”. Scientific Reports 5 (2015): 14830.
15. World Health Organization. “Coronavirus disease 2019 (COVID-19): situation report, 81” (2020).
16. Bradley KC., et al. “Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection”. Cell Reports1 (2019): 245-256.
17. Ma WT., et al. “The commensal microbiota and viral infection: a comprehensive review”. Frontiers in Immunology 10 (2019): 1551.
18. Pfeiffer JK and Virgin HW. “Transkingdom control of viral infection and immunity in the mammalian intestine”. Science6270 (2016): aad5872.
19. Uchiyama R., et al. “Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity”. The Journal of Infectious Diseases2 (2014): 171-182.
20. Jakobsson HE., et al. “Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section”. Gut 4 (2014): 559-566.
21. Tanoue T., et al. “Development and maintenance of intestinal regulatory T cells”. Nature Reviews Immunology5 (2016): 295.
22. Steed AL., et al. “The microbial metabolite desaminotyrosine protects from influenza through type I interferon”. Science6350 (2017): 498-502.
23. Wang Z., et al. “Inhibitory influence of Enterococcus faecium on the propagation of swine influenza A virus in vitro”. PloS one1 (2013).
24. Gonzalez-Perez G., et al. “Maternal antibiotic treatment impacts development of the neonatal intestinal microbiome and antiviral immunity”. The Journal of Immunology9 (2016): 3768-3779.
25. Huang Q and Herrmann A. “Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV)”. Bio Rxiv (2020).
26. Gu J., et al. “COVID-19: Gastrointestinal Manifestations and Potential Fecal-ral Transmission”. Gastroenterology (2020).
27. Jazayeri SD and Poh CL. “Recent advances in delivery of veterinary DNA vaccines against avian pathogens”. Veterinary Research1 (2019): 78.
28. Chen H., et al. “Genetic Operation System of Lactic Acid Bacteria and Its Applications”. In Lactic Acid Bacteria (2019): 35-76.
29. Szatraj K., et al. “Lactic acid bacteria-promising vaccine vectors: possibilities, limitations, doubts”. Journal of Applied Microbiology2 (2017): 325-339.
30. Plant KP and La Patra SE. “Advances in fish vaccine delivery?”. Developmental and Comparative Immunology 12 (2011): 1256-1262.
31. Sugimura T., et al. “Plasmacytoid dendritic cell dysfunction caused by heat stress is improved by administration of Lactococcus lactis strain plasma in mice”. Bioscience, Biotechnology, and Biochemistry 11 (2019): 2140-2143.
32. Biliavska L., et al. “Antiviral Activity of Exopolysaccharides Produced by Lactic Acid Bacteria of the Genera Pediococcus, Leuconostoc and Lactobacillus against Human Adenovirus Type 5”. Medicina9 (2019): 519.
33. Jung YJ., et al. “Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection”. Scientific Reports1 (2017): 1-12.
34. Huang KY., et al. “Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide”. Virus Research 247 (2018): 84-93.
35. Allain T., et al. “Bile-salt-hydrolases from the probiotic strain Lactobacillus johnsonii La1 mediate anti-giardial activity In vitro and In vivo”. Frontiers in Microbiology 8 (2018): 2707.
36. Hanchi H., et al. “The genus Enterococcus: Between probiotic potential and safety concerns-An update”. Frontiers in Microbiology 9 (2018): 1791.
37. Lauková A., et al. “Sensitivity to enterocins of biogenic amine-producing faecal enterococci from ostriches and pheasants”. Probiotics and Antimicrobial Proteins4 (2017): 483-491.
38. Pei H., et al. “Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination”. Applied Microbiology and Biotechnology2 (2005): 220-227.
39. Jiang X., et al. “A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection”. Applied Microbiology and Biotechnology17 (2016): 7457-7469.
40. Lee JS., et al. “Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice”. Journal of Virology8 (2006): 4079-4087.
41. Chai W., et al. “Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus”. Archives of Virology4 (2013): 799-807.

Citation

Citation: Shakira Ghazanfar., et al. “Lactic Acid Bacteria: Promising Role against Coronaviruses". Acta Scientific Nutritional Health 4.7 (2020): 43-48.

Copyright

Copyright: © 2020 Yuji Aoki., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.